Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study

This study aimed to compare the clinical progression of COVID-19 in high-risk outpatients treated with the monoclonal antibodies (mAb) bamlanivimab, bamlanivimab-etesevimab and casirivimab-imdevimab. This is an observational, multi-centre, prospective study conducted from 18 March to 15 July 2021 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoldi, Alessia, Morra, Matteo, De Nardo, Pasquale, Cattelan, Anna Maria, Mirandola, Massimo, Manfrin, Vinicio, Scotton, Piergiorgio, Giordani, Maria Teresa, Brollo, Lucio, Panese, Sandro, Lanzafame, Massimiliano, Scroccaro, Giovanna, Berkell, Matilda, Lippi, Giuseppe, Konnova, Angelina, Smet, Mathias, Malhotra-Kumar, Surbhi, Kumar-Singh, Samir, Tacconelli, Evelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209841/
https://www.ncbi.nlm.nih.gov/pubmed/35727429
http://dx.doi.org/10.1007/s10096-022-04464-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209841/
https://www.ncbi.nlm.nih.gov/pubmed/35727429
http://dx.doi.org/10.1007/s10096-022-04464-x

Ejemplares similares